Ride SharingNCT04564599
The Rise of Ride Sharing Companies and Trends in Impaired Driving Accidents
An observational study of Ride Sharing and Alcohol Drinking, run by Methodist Health System at 1 site in United States.
Trial summary
This will be a retrospective study with data collected from the trauma registry. We plan to complete the data collection and analysis by 12/31/2020. Data on ride sharing will be obtained from the Uber and Lyft websites. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Ride Sharing, Alcohol Drinking, Alcohol Intoxication
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jul 2023to 6 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This will be a retrospective study with data collected from the trauma registry. Patient population that will be looked at will be Males and Females 18 years or older who have tested positive for blood alcohol or drug screen and were involved Motor vehicle collision (MVC) or auto-ped.
Who may be able to join
- 18 years or older
- Positive blood alcohol or drug screen
- Motor vehicle collision (MVC) or auto-ped
Who cannot join
- Younger than 16 years
- Younger than 18 years
- Pregnant women
Trial locations and contacts
1 site in 1 country.
United States1 site
Methodist Dallas Medical Center
Dallas, Texas, 75203
About this study
Official title: The Rise of Ride Sharing Companies and Trends in Impaired Driving Accidents.
This will be a retrospective study with data collected from the trauma registry. We plan to complete the data collection and analysis by 12/31/2020. Data on ride sharing will be obtained from the Uber and Lyft websites. Data pertaining to number of alcohol- and drug-related motor vehicle (and auto-ped) collisions will be obtained from the Texas Department of Transportation website, the National Highway Traffic Safety Administration, the Shared-Use Mobility Center (SUMC) and the Transformation of Public Transit, the Texas A\&M Transportation Institute, Texas Department of Public Safety, and the U.S. Department of Transportation website (or equivalent). Sexual assault data will be obtained as available the Sexual Assault Nurse Examiner (SANE) database as well as from Turning Point Rape Crisis Center and surrounding hospitals in the Dallas area as well as the Uber report for sexual assaults.
Read the detailed description
- INTRODUCTION 1.1.1. Background Over the last decade, ride sharing services such as Uber and Lyft have become a popular transportation option, particularly for young people. These services often market themselves as less expensive and/or safer alternatives to taxis or driving while intoxicated (1). Whether ride sharing has a net benefit on rates of driving while intoxicated, or on alcohol and/or drug related crashes is unclear (2-6). Few studies have investigated this relationship, and a literature review showed no studies targeting the question outside of an isolated geographic region. Additionally, Uber has recently released its Safety Report bringing to light the issue of sexual assault associated with ride sharing. 1.1.2. Aim Investigate the relationship between ride sharing services and alcohol- and drug-related motor vehicle collisions within the state of Texas, and to develop understanding of the relationship between ride sharing services and sexual assault. 1.1.3. Rationale for the study The results of this study may be useful in public health initiatives to either incentivize or discourage ride sharing as a way to impact rates of alcohol- and drug-related motor vehicle collisions. Further, hospitals and insurance payors may be interested to note any calculated effect of ride sharing on hospital costs, lengths of stay, etc. 1.1.4. Hypothesis 1.1.4.1. Primary Hypothesis The introduction of ride sharing services such as Uber and Lyft to the state of Texas resulted in fewer alcohol- and drug-related crashes and greater cost savings for hospitals and insurance payors. 1.2. OBJECTIVES AND STUDY OUTCOME MEASURES 1.2.1. Study Objectives 1.2.1.1. Primary Objective(s)
- Determine the number and severity of alcohol- and/or drug-related motor vehicle collisions.
- Determine the number of auto vs pedestrian (auto-ped) alcohol- and/or drug-related collisions.
- Determine the correlation between the introduction of ride sharing services and the number of alcohol- and drug-related crashers as well as with hospital and insurance payor expenditures.
- Determine the relationship between ride sharing services and sexual assault. 1.2.2. Study Outcome Measures 1.2.2.1. Primary Outcomes
- Number of alcohol- and drug-related motor vehicle collisions
- Number of auto-ped alcohol- and drug-related collisions
- Results of alcohol screen and drug screens
- Mechanism of injury
- Metrics indicative of ride sharing service presence, use, and public awareness (i.e. self-reported usage and company reports)
- Additional information collected will include patient demographics, injury characteristics, injury severity score, abbreviated injury scale, emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost, hospital length of stay (LOS), ICU LOS, blood product data, vehicle type, number of sexual assaults, miles traveled, and mortality.
- STUDY DESIGN This will be a retrospective study with data collected from the trauma registry. We plan to complete the data collection and analysis by 12/31/2021. Data on ride sharing will be obtained from the Uber and Lyft websites. Data pertaining to number of alcohol- and drug-related motor vehicle (and auto-ped) collisions will be obtained from the Texas Department of Transportation website, the National Highway Traffic Safety Administration, the Shared-Use Mobility Center (SUMC) and the Transformation of Public Transit, the Texas A\&M Transportation Institute, Texas Department of Public Safety, and the U.S. Department of Transportation website (or equivalent). Sexual assault data will be obtained as available the Sexual Assault Nurse Examiner (SANE) database as well as from Turning Point Rape Crisis Center and surrounding hospitals in the Dallas area as well as the Uber report for sexual assaults.
- STUDY ENROLLMENT AND WITHDRAWAL 3.1. Study Inclusion Criteria:
- 18 years or older
- Positive blood alcohol or drug screen
- Motor vehicle collision (MVC) or auto-ped 3.2. Study Exclusion Criteria:
- Younger than 16 years
- Younger than 18 years
- Pregnant women 3.3. Premature Termination or suspension of study This study may be suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party. If the study is prematurely terminated or suspended, the principal investigator will promptly inform the IRB and will provide the reason(s) for suspension or termination. Circumstances that may warrant termination include, but are not limited to:
- Determination of unexpected, significant, or unacceptable risk to subjects.
- Insufficient adherence to protocol requirements.
- Data that is not sufficiently complete and/or evaluable.
- Determination of futility.
- Favorable outcomes at smaller than expected sample size.
- STATISTICAL CONSIDERATIONS 4.1. Sample Size Considerations This protocol is intended to be an observational study dependent on occurrence data. No formal sample size calculations were completed as this is limited by reported occurrences and retrospective analysis. 4.2. Statistical Analysis Plan Descriptive analysis will be performed for all variables. Frequencies, percentages, sensitivity, and specificity will be presented to summarize the categorical variables such as patient demographics and the outcomes of the different conditions associated with diaphragmatic injury. Mean and standard deviation will be presented for normally distributed continuous variables and median and interquartile range will be presented for non-normal continuous variables. The categorical outcome variables between the samples will be compared with chi square test or Fisher's exact test (if any cell value ≤ 5). The normally distributed continuous outcome variables will be analyzed with a two-sample t-test and non-normally distributed continuous outcomes will be analyzed with a nonparametric Wilcoxon-Mann-Whitney test. Because there might be potential for confounding patient characteristic variables to influence the outcome, a multiple regression and logistic model will be used to compensate for these factors. Odds ratio along with the confidence interval and p-value will be reported for both the adjusted and unadjusted model. A p-value <0.05 will be considered statistically significant.
- ETHICS/PROTECTION OF HUMAN SUBJECTS 5.1. Ethical Standard The investigator will ensure that this study is conducted in full conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, as drafted by the US National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6. If the study is conducted at international sites, the statement could be as above and/or could reference compliance with the Declaration of Helsinki, CIOMS, International Ethical Guidelines for Biomedical Research Involving Human Subjects (2002), or another country's ethical policy statement, whichever provides the most protection to human subjects. 5.2. Institutional Review Board The protocol will be submitted to the IRB for review and approval. Approval of the protocol must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented in the study. 5.3. Informed Consent Waiver Acquiring informed consent is not applicable. This study proposal is requesting a waiver of informed consent. This research only involves the collection or study of existing data, documents, and records and the investigators are recording information in such a manner that patients cannot be identified or possess any identifiers which could somehow be linked back to the patient. This research could not practicably be conducted without the waiver of informed consent because this is a retrospective chart review and it would be extremely time consuming to attempt contact for consent. Waiver of the HIPAA Authorization has been requested. The following reasons apply to our proposal: the use of the protected health information involves no more than the minimal risk of the privacy of the individuals, the research could not practicably be conducted without the waiver, and the research could not practicably be conducted without access to, and use of, the protected health information. 5.4. Participant Confidentiality All patient records and/or information will be kept under double locked doors or under password protection at all times. Only authorized study personnel as stated in the delegation of responsibility will have access to patient records and/or information.
- DATA MANAGEMENT PLAN 6.1. Source Document Management The source data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors or an encrypted, password protected Methodist Health System (MHS) approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy. 6.2. Data Capture Methods The data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors, or an encrypted, password protected MHS approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy.
- RECORD RETENTION/ARCHIVING All records pertaining to the study will be kept on site at Methodist Dallas Medical Center for three years upon study completion.
- PUBLICATION PLAN All studies must comply with GCP of blinding all protected health information of all patients prior to presentation and/or publication. The data obtained will be de-identified prior to sharing via presentation and/or publication in relevant research mediums. The data will be published and/or presented at national, regional, local and international sites. The research gathered will be analyzed and submitted to relevant medical journals for publication to add to the body of knowledge in the science community, as well as to improve on existing policies in trauma. This information may be presented at major surgical and trauma conferences including AAST (American Association for the Surgery of Trauma), SWSC (Southwest Surgical Congress), EAST (Eastern Association for the Surgery of Trauma), WTA (Western Trauma Association), etc.
- Conditions
- Ride Sharing, Alcohol Drinking, Alcohol Intoxication, Drug Use, Motor Collision, Sexual Assault
- Medical subject headings
- Alcohol Drinking, Alcoholic Intoxication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| alcohol- and drug-related motor vehicle collisions | Number of alcohol- and drug-related motor vehicle collisions | |
| auto-ped alcohol- and drug-related collisions | Number of auto-ped alcohol- and drug-related collisions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Results of alcohol screen and drug screens
Results of alcohol screen and drug screens
Measured: Data from January 1, 2000 to December 31, 2019
Mechanism of injury
Identify the Mechanism of injury for each collision ( alcohol vs. drug related)
Measured: Data from January 1, 2000 to December 31, 2019
Metrics indicative of ride sharing service presence, use, and public awareness
self-reported usage and company reports
Measured: Data from January 1, 2000 to December 31, 2019
Patient demographics
Patient demographics
Measured: Data from January 1, 2000 to December 31, 2019
injury characteristics
injury characteristics
Measured: Data from January 1, 2000 to December 31, 2019
injury severity score
injury severity score
Measured: Data from January 1, 2000 to December 31, 2019
abbreviated injury scale
abbreviated injury scale
Measured: Data from January 1, 2000 to December 31, 2019
hospital length of stay (LOS)
hospital length of stay (LOS)
Measured: Data from January 1, 2000 to December 31, 2019
emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost
emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost
Measured: Data from January 1, 2000 to December 31, 2019
ICU Length of Stay (LOS)
ICU Length of Stay (LOS)
Measured: Data from January 1, 2000 to December 31, 2019
blood product data
blood product data
Measured: Data from January 1, 2000 to December 31, 2019
vehicle type
vehicle type
Measured: Data from January 1, 2000 to December 31, 2019
number of sexual assaults
number of sexual assaults
Measured: Data from January 1, 2000 to December 31, 2019
miles traveled
miles traveled
Measured: Data from January 1, 2000 to December 31, 2019
mortality
mortality
Measured: Data from January 1, 2000 to December 31, 2019
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2020
- Study start6 Jul 2023
- Primary completion6 Jun 2025
- Study completion6 Jun 2025
Why it stopped: PI left institution
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ride SharingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Crystee Cooper, DHEd, Study director, Methodist Health System Clinical Research InstituteMichael Truitt, MD, Principal investigator, Methodist Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04564599
- Sponsor's protocol ID
- 004.GME.2020.D
- Status last verified
- Jun 2025
- First submitted
- 21 Sep 2020
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The source data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors or an encrypted, password protected Methodist Health System (MHS) approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy.
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Rise of Ride Sharing Companies and Trends in Impaired Driving Accidents.
- ClinicalTrials.gov ID
- NCT04564599
- Acronym / sponsor ID
- 004.GME.2020.D
- Conditions
- Ride Sharing, Alcohol Drinking, Alcohol Intoxication, Drug Use, Motor Collision, Sexual Assault
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: PI left institution
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 6 Jul 2023 (actual)
- Primary completion
- 6 Jun 2025 (actual)
- Study completion
- 6 Jun 2025 (actual)
- First posted
- 25 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This will be a retrospective study with data collected from the trauma registry. We plan to complete the data collection and analysis by 12/31/2020. Data on ride sharing will be obtained from the Uber and Lyft websites. Data pertaining to number of alcohol- and drug-related motor vehicle (and auto-ped) collisions will be obtained from the Texas Department of Transportation website, the National Highway Traffic Safety Administration, the Shared-Use Mobility Center (SUMC) and the Transformation of Public Transit, the Texas A\&M Transportation Institute, Texas Department of Public Safety, and the U.S. Department of Transportation website (or equivalent). Sexual assault data will be obtained as available the Sexual Assault Nurse Examiner (SANE) database as well as from Turning Point Rape Crisis Center and surrounding hospitals in the Dallas area as well as the Uber report for sexual assaults.
Detailed description
- INTRODUCTION 1.1.1. Background Over the last decade, ride sharing services such as Uber and Lyft have become a popular transportation option, particularly for young people. These services often market themselves as less expensive and/or safer alternatives to taxis or driving while intoxicated (1). Whether ride sharing has a net benefit on rates of driving while intoxicated, or on alcohol and/or drug related crashes is unclear (2-6). Few studies have investigated this relationship, and a literature review showed no studies targeting the question outside of an isolated geographic region. Additionally, Uber has recently released its Safety Report bringing to light the issue of sexual assault associated with ride sharing. 1.1.2. Aim Investigate the relationship between ride sharing services and alcohol- and drug-related motor vehicle collisions within the state of Texas, and to develop understanding of the relationship between ride sharing services and sexual assault. 1.1.3. Rationale for the study The results of this study may be useful in public health initiatives to either incentivize or discourage ride sharing as a way to impact rates of alcohol- and drug-related motor vehicle collisions. Further, hospitals and insurance payors may be interested to note any calculated effect of ride sharing on hospital costs, lengths of stay, etc. 1.1.4. Hypothesis 1.1.4.1. Primary Hypothesis The introduction of ride sharing services such as Uber and Lyft to the state of Texas resulted in fewer alcohol- and drug-related crashes and greater cost savings for hospitals and insurance payors. 1.2. OBJECTIVES AND STUDY OUTCOME MEASURES 1.2.1. Study Objectives 1.2.1.1. Primary Objective(s)
- Determine the number and severity of alcohol- and/or drug-related motor vehicle collisions.
- Determine the number of auto vs pedestrian (auto-ped) alcohol- and/or drug-related collisions.
- Determine the correlation between the introduction of ride sharing services and the number of alcohol- and drug-related crashers as well as with hospital and insurance payor expenditures.
- Determine the relationship between ride sharing services and sexual assault. 1.2.2. Study Outcome Measures 1.2.2.1. Primary Outcomes
- Number of alcohol- and drug-related motor vehicle collisions
- Number of auto-ped alcohol- and drug-related collisions
- Results of alcohol screen and drug screens
- Mechanism of injury
- Metrics indicative of ride sharing service presence, use, and public awareness (i.e. self-reported usage and company reports)
- Additional information collected will include patient demographics, injury characteristics, injury severity score, abbreviated injury scale, emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost, hospital length of stay (LOS), ICU LOS, blood product data, vehicle type, number of sexual assaults, miles traveled, and mortality.
- STUDY DESIGN This will be a retrospective study with data collected from the trauma registry. We plan to complete the data collection and analysis by 12/31/2021. Data on ride sharing will be obtained from the Uber and Lyft websites. Data pertaining to number of alcohol- and drug-related motor vehicle (and auto-ped) collisions will be obtained from the Texas Department of Transportation website, the National Highway Traffic Safety Administration, the Shared-Use Mobility Center (SUMC) and the Transformation of Public Transit, the Texas A\&M Transportation Institute, Texas Department of Public Safety, and the U.S. Department of Transportation website (or equivalent). Sexual assault data will be obtained as available the Sexual Assault Nurse Examiner (SANE) database as well as from Turning Point Rape Crisis Center and surrounding hospitals in the Dallas area as well as the Uber report for sexual assaults.
- STUDY ENROLLMENT AND WITHDRAWAL 3.1. Study Inclusion Criteria:
- 18 years or older
- Positive blood alcohol or drug screen
- Motor vehicle collision (MVC) or auto-ped 3.2. Study Exclusion Criteria:
- Younger than 16 years
- Younger than 18 years
- Pregnant women 3.3. Premature Termination or suspension of study This study may be suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party. If the study is prematurely terminated or suspended, the principal investigator will promptly inform the IRB and will provide the reason(s) for suspension or termination. Circumstances that may warrant termination include, but are not limited to:
- Determination of unexpected, significant, or unacceptable risk to subjects.
- Insufficient adherence to protocol requirements.
- Data that is not sufficiently complete and/or evaluable.
- Determination of futility.
- Favorable outcomes at smaller than expected sample size.
- STATISTICAL CONSIDERATIONS 4.1. Sample Size Considerations This protocol is intended to be an observational study dependent on occurrence data. No formal sample size calculations were completed as this is limited by reported occurrences and retrospective analysis. 4.2. Statistical Analysis Plan Descriptive analysis will be performed for all variables. Frequencies, percentages, sensitivity, and specificity will be presented to summarize the categorical variables such as patient demographics and the outcomes of the different conditions associated with diaphragmatic injury. Mean and standard deviation will be presented for normally distributed continuous variables and median and interquartile range will be presented for non-normal continuous variables. The categorical outcome variables between the samples will be compared with chi square test or Fisher's exact test (if any cell value ≤ 5). The normally distributed continuous outcome variables will be analyzed with a two-sample t-test and non-normally distributed continuous outcomes will be analyzed with a nonparametric Wilcoxon-Mann-Whitney test. Because there might be potential for confounding patient characteristic variables to influence the outcome, a multiple regression and logistic model will be used to compensate for these factors. Odds ratio along with the confidence interval and p-value will be reported for both the adjusted and unadjusted model. A p-value <0.05 will be considered statistically significant.
- ETHICS/PROTECTION OF HUMAN SUBJECTS 5.1. Ethical Standard The investigator will ensure that this study is conducted in full conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, as drafted by the US National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6. If the study is conducted at international sites, the statement could be as above and/or could reference compliance with the Declaration of Helsinki, CIOMS, International Ethical Guidelines for Biomedical Research Involving Human Subjects (2002), or another country's ethical policy statement, whichever provides the most protection to human subjects. 5.2. Institutional Review Board The protocol will be submitted to the IRB for review and approval. Approval of the protocol must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented in the study. 5.3. Informed Consent Waiver Acquiring informed consent is not applicable. This study proposal is requesting a waiver of informed consent. This research only involves the collection or study of existing data, documents, and records and the investigators are recording information in such a manner that patients cannot be identified or possess any identifiers which could somehow be linked back to the patient. This research could not practicably be conducted without the waiver of informed consent because this is a retrospective chart review and it would be extremely time consuming to attempt contact for consent. Waiver of the HIPAA Authorization has been requested. The following reasons apply to our proposal: the use of the protected health information involves no more than the minimal risk of the privacy of the individuals, the research could not practicably be conducted without the waiver, and the research could not practicably be conducted without access to, and use of, the protected health information. 5.4. Participant Confidentiality All patient records and/or information will be kept under double locked doors or under password protection at all times. Only authorized study personnel as stated in the delegation of responsibility will have access to patient records and/or information.
- DATA MANAGEMENT PLAN 6.1. Source Document Management The source data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors or an encrypted, password protected Methodist Health System (MHS) approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy. 6.2. Data Capture Methods The data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors, or an encrypted, password protected MHS approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy.
- RECORD RETENTION/ARCHIVING All records pertaining to the study will be kept on site at Methodist Dallas Medical Center for three years upon study completion.
- PUBLICATION PLAN All studies must comply with GCP of blinding all protected health information of all patients prior to presentation and/or publication. The data obtained will be de-identified prior to sharing via presentation and/or publication in relevant research mediums. The data will be published and/or presented at national, regional, local and international sites. The research gathered will be analyzed and submitted to relevant medical journals for publication to add to the body of knowledge in the science community, as well as to improve on existing policies in trauma. This information may be presented at major surgical and trauma conferences including AAST (American Association for the Surgery of Trauma), SWSC (Southwest Surgical Congress), EAST (Eastern Association for the Surgery of Trauma), WTA (Western Trauma Association), etc.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| alcohol- and drug-related motor vehicle collisions | – | –Number of alcohol- and drug-related motor vehicle collisions |
| auto-ped alcohol- and drug-related collisions | – | –Number of auto-ped alcohol- and drug-related collisions |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This will be a retrospective study with data collected from the trauma registry. Patient population that will be looked at will be Males and Females 18 years or older who have tested positive for blood alcohol or drug screen and were involved Motor vehicle collision (MVC) or auto-ped.
Key inclusion criteria (3 listed)
- 18 years or older
- Positive blood alcohol or drug screen
- Motor vehicle collision (MVC) or auto-ped
Key exclusion criteria (3 listed)
- Younger than 16 years
- Younger than 18 years
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Results of alcohol screen and drug screens
Time frame: Data from January 1, 2000 to December 31, 2019
Results of alcohol screen and drug screens
Mechanism of injury
Time frame: Data from January 1, 2000 to December 31, 2019
Identify the Mechanism of injury for each collision ( alcohol vs. drug related)
Metrics indicative of ride sharing service presence, use, and public awareness
Time frame: Data from January 1, 2000 to December 31, 2019
self-reported usage and company reports
Patient demographics
Time frame: Data from January 1, 2000 to December 31, 2019
Patient demographics
injury characteristics
Time frame: Data from January 1, 2000 to December 31, 2019
injury characteristics
injury severity score
Time frame: Data from January 1, 2000 to December 31, 2019
injury severity score
abbreviated injury scale
Time frame: Data from January 1, 2000 to December 31, 2019
abbreviated injury scale
hospital length of stay (LOS)
Time frame: Data from January 1, 2000 to December 31, 2019
hospital length of stay (LOS)
emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost
Time frame: Data from January 1, 2000 to December 31, 2019
emergency department vitals, diagnoses, procedures, insurance coverage, treatment cost
ICU Length of Stay (LOS)
Time frame: Data from January 1, 2000 to December 31, 2019
ICU Length of Stay (LOS)
blood product data
Time frame: Data from January 1, 2000 to December 31, 2019
blood product data
vehicle type
Time frame: Data from January 1, 2000 to December 31, 2019
vehicle type
number of sexual assaults
Time frame: Data from January 1, 2000 to December 31, 2019
number of sexual assaults
miles traveled
Time frame: Data from January 1, 2000 to December 31, 2019
miles traveled
mortality
Time frame: Data from January 1, 2000 to December 31, 2019
mortality
Results and safety
The study was stopped early (reason given: PI left institution). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
- Individual participant dataSharing planned: No. The source data will be collected with the assistance of the electronic medical/health record software, Premier, Midas or other medical/hospital data sources, paper records and/or electronic data collection methods. All data collected will be entered into an Excel sheet and recorded. All data collection methodologies will be maintained under strict surveillance, double locked doors or an encrypted, password protected Methodist Health System (MHS) approved server. All data capture and storage methods will be HIPAA compliant as per MHS policy.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Crystee Cooper, DHEd study director
Methodist Health System Clinical Research Institute
Michael Truitt, MD principal investigator
Methodist Health System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ride Sharing and Alcohol Drinking, run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: PI left institution). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Results of alcohol screen and drug screens (time frame: Data from January 1, 2000 to December 31, 2019). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.